In 2005, the city and state of New York launched New York/New York III (NY/NY III), a permanent supportive housing program for individuals experiencing homelessness or at risk of homelessness with complex medical and behavioral health issues. This review paper summarizes a decade of findings (2007-2017) from the NY/NY III evaluation team, to analyze this program's impact on various housing and health outcomes. The evaluation team linked NY/NY III eligible persons with administrative data from two years pre- and two years post-eligibility and compared housing and health outcomes between placed and unplaced groups using propensity score analysis. Placement into NY/NY III housing was associated with improved physical and mental health outcomes, increased housing stability, and statistically significant cost savings per person after one year of placement. The evaluation team recommends that municipalities invest in supportive housing as a means for mitigating homelessness and improving health outcomes in this vulnerable population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.evalprogplan.2023.102245 | DOI Listing |
Eval Program Plann
April 2023
Bureau of Epidemiology Services, New York City Department of Health and Mental Hygiene, 42-09 28th St, 7th Floor, Queens, NY 11101, USA.
In 2005, the city and state of New York launched New York/New York III (NY/NY III), a permanent supportive housing program for individuals experiencing homelessness or at risk of homelessness with complex medical and behavioral health issues. This review paper summarizes a decade of findings (2007-2017) from the NY/NY III evaluation team, to analyze this program's impact on various housing and health outcomes. The evaluation team linked NY/NY III eligible persons with administrative data from two years pre- and two years post-eligibility and compared housing and health outcomes between placed and unplaced groups using propensity score analysis.
View Article and Find Full Text PDFClin Cancer Res
November 2010
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA.
Purpose: Phase II clinical studies screen for treatment regimens that improve patient care, but screening combination regimens is especially challenging. We hypothesized that recognized flaws of single-arm trials could be magnified in combination treatment studies, leading to many reported positive phase II trials but with a low fraction resulting in practice-changing phase III trials.
Experimental Design: We searched medline and identified 363 combination chemotherapy clinical trials published in 2001 and 2002.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!